Podcasts about dtx

En este programa hacemos un repaso a algunas noticias de la actualidad commodoriana y a los lanzamientos de las últimas semanas, y veremos la revista alemana 64'er, concretamente su número 2/85. Todo esto lo veremos con el equipo habitual formado por David Asenjo (https://twitter.com/darro99), Toni Bianchetti (https://twitter.com/seuck), Narciso Quintana "Narcisound" (https://twitter.com/narcisound), Jonatan Jiménez (https://twitter.com/jsabreman) y Paco Herrera (https://twitter.com/pacoblog64). Las noticias comentadas son: - Preservados varios spots de 15 segundos de Amiga del año 1988: https://www.youtube.com/watch?v=DtUfT6Hdn8Q - Primera versión del manual del KIM-1 en proceso de preservación.: https://drive.google.com/drive/folders/1ZxhtmIP3VOtGXLsINfK0gIUDoB1DIzVF?usp=drive_link - La revista Commodoriani sigue su andadura: https://commodore.inc/commodoriani/ - Concurso de BASIC en 10 líneas, edición de 2025: https://gkanold.wixsite.com/homeputerium/rules2025 - 5ª edición del Torneo Vasco de Commodore 64 y la 7ª en su versión Amiguera: https://www.commodoreplus.org/2025/01/torneo-vasco-de-commodore-64.html - Reparación de una consola Commodore 2000K: https://www.youtube.com/watch?v=5kamx4BkMxM - Actualización del portal C64.ch: https://c64.ch/ - KickSmash 32: Nuevo sustituto para chips ROM Kickstart para Amiga 3000 y 4000: https://github.com/cdhooper/kicksmash32 - SMD2000 "Bushfire", nueva placa mini-DTX que replica el Amiga 2000: https://www.amigaretro.com/projects/introducing-the-smd2000-bushfire/; https://github.com/gazzmaniac/SMD2000/ - Libro sobre Jaz Rignall, redactor de Zzap!64: https://www.bitmapbooks.com/products/the-games-of-a-lifetime?srsltid=AfmBOopW62W8DcquG7h0M8ycqxcd9Wp0jOqiHDPCH4HybIc0zeuN-GOe - Amiga Rocks Harder (Fastloaders): https://www.kickstarter.com/projects/fastloaders/amiga-rocks-harder-by-fastloaders - Resultados de los Premios Commodoremanía: https://commodoremania.com/foro/index.php/topic,2894 - Abierta las pre ventas para el especial numero 3 de FREEZE64: https://freeze64.com/2025/02/21/preorder-freeze64-maps-levels-special/ - La Video Game History Foundation abrirá al público y gratis su biblioteca digital con miles de materiales sobre la historia de los videojuegos: https://www.adslzone.net/noticias/videojuegos/libreria-online-historia-videojuegos/ - Nuevo libro sobre Commodore 64 en Kickstarter: https://www.kickstarter.com/projects/beyondtheborders/redo-from-start-volume-i - Atari lanza un reloj para conmemorar el 45 aniversario de Asteroids: https://nubeowatches.com/collections/atari-limited-edition/products/ventana-automatic-atari-asteroids-45th-limited-edition-celestial-citrine-nb-6111-03 Actualizaciones: - AmiKit 12.7: https://www.amikit.amiga.sk/ - Versatile Amiga Test Program v6.45: https://aminet.net/package/util/misc/VATestprogram - Albert v2.4: https://www.albertpixels.com https://csdb.dk/release/?id=249041 Los juegos y programas nuevos comentados son: - Docster's Digger (TRP, Plus/4): https://plus4world.powweb.com/software/Docsters_Digger - Matrix (Entary Games, Plus/4): https://plus4world.powweb.com/software/Matrix_Entary_Games - Avalan (Psytronik, C64): https://psytronik.itch.io/avalan - B Breakout (Haegar, Plus/4): https://plus4world.powweb.com/software/B-Breakout - Elite (Aleksi Eben, VIC-20): https://vic20elite.wordpress.com/ - White Max (TomHX, Plus/4): https://plus4world.powweb.com/software/White_Max - Safe Zone (Frank Abbing, C64): https://frank-abbing.itch.io/safe-zone - The End of the World (Frank Abbing, C64): https://frank-abbing.itch.io/the-end-of-the-world - Huck on the Mississipi (Frank Abbing, C64): https://frank-abbing.itch.io/huck-on-the-mississippi - Platman MC (Wanaz, C64): https://wanax.itch.io/platman-mc - Kuusneppis (Artline Desings, C64): https://artlinedesigns.itch.io/kuusneppis - Beyond the door (spotlessmind1975, C64): https://spotlessmind1975.itch.io/btd-10liner - Mike Mech 2 (LC-Games, C64): https://lowcarb.itch.io/mike-mech-2-c64 - Shock Raid (Richard of TND, C64): https://richard-tnd.itch.io/shock-raid-64 - SnailRace (Bunsen, C64): https://bunsen.itch.io/snailrace-commodore-64-by-metzelwurst - Ladybird (Psytronik Software, C64): https://psytronik.itch.io/ladybird - Le Bubblo Massacro (Misfit, C64): https://misfit.itch.io/le-bubbl-massacr-c64 - Commodore Zone PDF Collection (Psytronik Software, C64): https://psytronik.itch.io/czone - Goal - Hockey Soccer Football (Jeffrey Daniels, VIC-20): https://jeffdaniels.itch.io/goal-hockey-soccer-football-vic-20-vic-20-vic20 - Pas 6502 (syntaxerrorsoftware, C64): https://syntaxerrorsoftware.itch.io/pas6502 - Super Star Wars - Holiday Special AGA (earok, Amiga): https://eab.abime.net/showthread.php?p=1725394#post1725394 - Erinia (Dareint, C64): https://dareint.itch.io/erinia-2025-english - Absolute Zero (Zener, Sandman y Fireboy, Amiga): https://zener.itch.io/absolute-zero

Was sind eigentlich Digital Therapeutics (DTx)? Und was braucht es, damit diese in der Schweiz in Zukunft Anwendung finden?

In this week's Digital Health Roundup, Medtech Insight's Ryan Nelson highlights Click Therapeutics' FDA-cleared digital therapeutics (DTx) for depression and Sinaptica Therapeutics' personalized neuromodulation for Alzheimer's patients. Marion Webb discusses her interview with MindMaze's John Krakauer on their gaming-focused DTx to help people recover from serious brain injuries. Elizabeth Orr introduces new voting members of the new Digital Health Advisory Committee and Natasha Barrow discusses Hello Heart's new symptom-tracking feature in their heart-focused app. Stories discussed in this episode: MindMaze, ‘A Ratio Of Luke Skywalker And R2-D2', Navigates The DTx Galaxy Click Therapeutics Anticipates Pharma Will Begin Developing Digital Drugs From Clinical Stage Sinaptica On Precision Neuromodulation To Combat Alzheimer's: ‘No Drug Dares Go After Moderate Patients' DHCoE-AI-Lifecycle-Management-Plan-To-Serve-As-Playbook-For-Standards Hello Heart Says Update To Cardiovascular Health Tracker Could Benefit Women Especially

Welcome to the DTx Podcast, where we explore the latest in digital therapeutics. In our previous episode with Mike Pace, we discussed the challenges facing DTx in 2023. Now, with positive developments in 2024, we're updating our community on the progress in advancing digital therapies. Host Eugene Borukhovich engages with experts Dr. Jenna Carl, Andy Molnar, Marty Culjat, and Kirsten Tullia to discuss the latest trends, challenges, and opportunities in the DTx industry. [00:30] Expanding US channels and mental health access [05:15] Software-wearable integration and commercial models [12:45] Coverage expansion impact on Medicare and Medicaid [18:10] Evolution of DTx and reimbursement challenges [23:30] Investor impatience and R&D impact [28:00] Medicare reimbursement and investor interest in DTx Tune in to the DTx Podcast to gain valuable insights into the evolving world of digital therapeutics and stay updated on the latest trends, legislative impacts, and entrepreneurial advice from industry leaders. If you'd like to learn more about sponsorship opportunities across Mission Based Media assets, visit our website at https://missionbasedmedia.com/ Guest Links and Resources: Connect with Dr. Jenna Carl on Linkedin Connect with Andy Molnar on Linkedin Connect with Marty Culjat on Linkedin Connect with Kirsten Tullia on Linkedin Listen to the episode with Mike Pace Host Links: Connect with Eugene Borukhovich: Twitter | LinkedIn Connect with YourCoach.health: Website | Twitter Check out Shot of Digital Health with Eugene and Jim Joyce: Website | Podcast App Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram

On June 27, 2024 we discussed AI in Life Sciences with Jot Chahal, Johnson & Johnson, Patricia Leuchten, Diligent Pharma and V. "Bala" Balasubramanian, PhD, MBA, Orion InnovationJot Chahal is Vice President, Global Digital Health at Johnson & Johnson Innovative Medicine, where he is accelerating the commercialization of digital health assets across the pharmaceutical business.Partnering with our regions, technology, and R&D leaders across the globe to build digital health (SaMD, DTx) capabilities and drive business growth across all therapy areas.He is an entrepreneurial and results-driven health technology executive with twenty years of experience in driving top-line profitable growth through innovation, and data-driven strategies across industries, services, and markets globally.Patti Leuchten is a pharma industry leader and entrepreneur with a focus on driving improvements in clinical trial execution, at scale, through innovative solutions.In 1999, she founded The Avoca Group, whose Avoca Quality Consortium paved the way for Diligent Pharma and the Diligent Qualification Platform.Dr. V. “Bala” Balasubramanian is currently SVP and Global Head of Industry Solutions Group for Healthcare and Life Sciences at Orion Innovation.He is responsible for defining the GTM strategy, solution and service offerings for the HLS division, exploring digital transformation initiatives to further the needs of clients, and providing thought leadership to the industry.It has resulted in Orion being featured in Gartner and Everest Peak Matrix Benchmark Reports in 2022 and 2023. He has recently written about opportunities and challenges with respect to GenAI in Life Sciences.Prior to Orion, Bala was the Co-Founder and CEO of Cabeus where he was responsible for strategy, leadership and vision for both service offerings and a cloud platform to transform the regulatory value chain for Life Sciences.#ai #drugdiscovery #clinicaltrials#podcast #AFewThingsPodcast

This week we wrap up the conversations at the exocad (https://exocad.com/) Insights 2024 meeting from Mallorca, Spain. Elvis and Barb can not thank exocad enough for this amazing opportunity to showcase some many AMAZING people in our industry. Things were learned, friends were made, laptops were returned, and memories were made. Thank you exocad! First up is dental technician that is working on business development at Nobel Biocare (https://www.nobelbiocare.com/en-us), Chuck Genco. Chuck is 35 year veteran in various dental labs. He's now with Nobel Biocare helping them create a solution based digital workflow with a emphasis on "time to teeth". He talks about his journey, his role at Nobel, and what some interesting things they are working on. Then we talk to two friends in Spain, from Syria, working in Sweden. Yousef Ibrahim is a ceramist. Maher Al Hanfeish is the cad/cam technician. After leaving Syria, they both found their way to the same lab in Sweden and have been friends ever since. They talk about their journey into the lab, getting to Sweden, and their daily life in a lab. As a special BONUS, we talk to the Chair of the Foundation for Dental Laboratory Technology (https://dentallabfoundation.org/), Jen Ludwig and the Executive Director, Lindsey Rowan. They both come on to talk about the upcoming Race for the Future happening on September 15th, 2024 in Fort Worth, Texas. Join the Race: https://fdlt.memberclicks.net/donor-form DONATE TODAY: https://fortworth.californiatriathlon.org/Race/Register/?raceId=99407 Introducing Ivotion Digital Dentures (https://www.ivoclar.com/en_us/products/digital-processes/ivotion) from Ivoclar (https://www.ivoclar.com/en_us) – Experience unparalleled precision and efficiency with Ivoclar‘s state-of-the-art digital denture workflow. Ivotion is available in their patent pending monolithic disc that combines denture base and tooth materials in one seamless puck. Or if you lab needs more flexibility, Ivotion is also available as stand-alone discs - Ivotion Base, Dent and Dent Multi all in 98mm width to fit your favorite milling machine. With Ivotion you can streamline your lab's processes, reduce production time, and enhance patient satisfaction. Elevate your lab's capabilities with Ivotion Digital Dentures – where innovation meets perfection. Discover the future of dentures today with Ivoclar." Thanks for your continued support of the podcast Ivoclar. Join the GOLDEN BENCH CLUB! All you have to do is leave us a 5-star review and comment on the Apple Podcast app (or any other app and email us a screen shot) and we will read your review on the podcast and welcome you to the Golden Bench Club. This super elite club is only for the best of the best. Special Guests: Chuck Genco, Jennifer Ludwig, CDT, Lindsey Rowan, Maher Al Hanfeish , and Yousef Ibrahim.

Join us for an engaging podcast episode as we unpack the key insights from the Government Finance Officers Association 2024 conference. In this session, we'll zoom in on the essential lessons that CFOs (Chief Financial Officers) must grasp for successful Digital Transformation (DtX) projects. Our seasoned experts will dissect strategies, share best practices, and delve into real-world case studies, providing actionable insights to empower CFOs in navigating the intricacies of DtX initiatives. Whether you're a seasoned CFO well-versed in DtX or new to the concept, this podcast promises invaluable knowledge to foster innovation and enhance efficiency within your organization. Tune in for an enlightening discussion on the future of finance in an increasingly digital age!Stay up to date on industry trends!Top 10 Public Sector ERP Systems: ➡ https://tinyurl.com/4bcduptpLearn More About Avero:➡ https://www.averoadvisors.comConnect With Us:LinkedIn: https://www.linkedin.com/company/averoadvisorsFacebook: https://www.facebook.com/averoadvisorsInstagram: https://www.instagram.com/averoadvisorsTikTok: https://www.tiktok.com/@averoadvisorsConnect With AV:LinkedIn: https://www.linkedin.com/in/verekar(865) 415-3848 | info@averoadvisors.com

'Digital transformation' is a term widely, and often badly, used.  It generally gets used to describe simply digitising a process and making what we already do run more efficiently.  However, good DTx is far more than that...This week, Dave and Rob talk to Nathan Clark, Founder & CEO of Ganymede, about how their platform provides data in the right place, at the right time, and in the right order across the laboratory process in biotech. They discuss how this functions, the outcomes it improves, and whether it provides a useful case study for what good digital transformation looks like. TLDR:02:30 Is Rob confused about being a super hero in the Matrix?05:40: Cloud Biotech conversation with Nathan Clark31:50:  Will the the future bring the Star Trek communicator? 37:50: Buying a house in New York!GuestNathan Clark: https://www.linkedin.com/in/nathan-clark-4b850134/HostsDave Chapman: https://www.linkedin.com/in/chapmandr/Rob Kernahan: https://www.linkedin.com/in/rob-kernahan/ProductionMarcel Van Der Burg: https://www.linkedin.com/in/marcel-van-der-burg-99a655/Dave Chapman: https://www.linkedin.com/in/chapmandr/SoundBen Corbett: https://www.linkedin.com/in/ben-corbett-3b6a11135/Louis Corbett:  https://www.linkedin.com/in/louis-corbett-087250264/

On this episode of the podcast, I am joined by recording artist DTX. This episode started a little different than the last with DTX detailing his experience in foster care to how he ended up falling in love with music. Please like, share and subscribe.Support this podcast at — https://redcircle.com/the-no-cap-podcast/donations

In the last few years, we've witnessed a whirlwind of developments in the world of Digital Therapeutics (DTx) - from FDA approvals sparking optimism for the industry, to the establishment of regulatory frameworks in countries like Germany, France, and Belgium. However, in 2023, the industry faced a stark reality check, marked by the fall of some key players and healthcare systems' hesitancy towards embracing and financing these innovations. This turbulence has reshaped strategies and raised critical questions about the future of DTx.

Did you know that Belgium has had an idea for classifying and validating digital therapeutics since 2018? A clear framework was formed with all main stakeholders involved - from health insurance to the industry. So why are we not hearing more about DTx in Belgium? In this discussion you will hear from Dr. Steven Vandeput -  he is the Advisor for Digital MedTech and Services & Technologies Home Assistance in Belgium; he is managing the mHealthBelgium portal and, since 2019, has been a representative for beMedTech, the sector federation that represents the industry of medical technologies in Belgium.  Website: www.facesofdigitalhealth.com Newsletter: https://fodh.substack.com/ Show notes: 00:00 - Introduction 01:45 - Digital Therapeutics in Belgium 03:50 - Belgium's Healthcare Framework Development 06:00 - The Validation Pyramid and Reimbursement System 08:00 - Fate of Pilot Projects and Their Impact 10:00 - Utilization of mHealth Belgium Portal 12:00 - Challenges in Reimbursement and Financing 14:00 - Prospects for Digital Therapeutic Companies 16:00 - Belgium's Approach to Financing Digital Health 18:00 - Anticipations for the Digital Health Field 20:00 - The Evolving European Frameworks 22:00 - Impact of Political Decisions and Healthcare System Integration 24:00 - The Future of mHealth Belgium Platform

We caught up with Amit Shah and he discussed Virta's mission to reverse Type 2 diabetes and obesity through personalized nutrition and continuous remote monitoring. He also discusses he challenges of scaling Virta's pioneering clinical, technology, and business model - including evolving massive workflows and systems amid rapid growth and how recent GLP-1 obesity drug approvals are tailwinds driving adoption of Virta's more sustainable, cost-effective solution. Amit Shah: https://www.linkedin.com/in/amitrshah1/Chris Hoyd: https://www.linkedin.com/in/chrishoyd/For the full YouTube video: https://youtu.be/Fl-_SsHEz0YVirta Health Website: https://www.virtahealth.com/Virta Health YouTube: https://www.youtube.com/virtahealth Product in Healthtech is community for healthtech product leaders, by product leaders. For more information, and to sign up for our free webinars, visit www.productinhealthtech.com.

In 2023, Insilico Medicine—a biotech company developing medications with a heavy reliance on AI—used AI to develop an experimental drug for the incurable lung disease idiopathic pulmonary fibrosis. The treatment is in mid-stage trials in the US and China, with some results expected in early 2025. Biotech is one of the fields that has been using generative AI for years, even before ChatGPT brought the technology to public view. Latest technology is essential in drug development. However, the convergence of digital health and pharma seems less clear. Digital health apps started gaining popularity around 2015, and at that time, it seemed all pharma companies were trying to figure out what they could gain from apps, so they financed accelerators and incubators one after the other. We've seen many ideas about how Pharma should or could use digital health. In the last few years, there have been many notorious cases when partnerships failed—a seemingly unicorn, Proteus, which designed digital sensors-equipped pills, went bankrupt in 2019 after Otsuka Pharmaceuticals pulled out of a funding round. Pear Therapeutics, the guiding star in the DTx space and the leader in FDA-cleared prescription digital therapeutics, partnered with Novartis, but in the end, the company filed for bankruptcy in 2023. So where is Pharma in relation to digital health and digital therapeutics? In this episode, Amir Lahav shares his thoughts about the impact of AI on biotech, the state of decentralized clinical trials, and the potential of technology for improved drug development, clinical trials, and patient responses. Newsletter: https://fodh.substack.com/ www.facesofdigitalhealth.com Show notes: [00:02:00] The Convergence of Digital Health and Pharma Discussion on the role of digital health apps in pharmaceuticals. The rise and fall of pharma and tech company partnerships, with examples like Proteus and Peer Therapeutics. [00:06:00] AI Trends in Biotech and Pharma [00:08:00] Enhancing Clinical Trials with AI and continuous patient monitoring [00:10:00] The Importance of Data in Clinical Trials [00:12:00] The Reality of Oncology Trials and Endpoints [00:14:00] Quality of Life in Medicine as the Endpoint [00:16:00] The Rise of Decentralized Clinical Trials [00:18:00] Pharma's Evolving Digital Health Strategies [00:22:00] Impact on Digital Health Industry [00:24:00] Collaboration and Sharing Knowledge in the Pharma Industry [00:26:00] The need for long-term investment and strategic piloting of digital health solutions [00:28:00] What Inspires in Pharma and Biotech in Personalized Treatments [00:30:00] The State of Precision Medicine and Targeted Therapies [00:34:00] The Role of Pharmacogenomics [00:36:00] Anticipations for 2024 and Beyond

In this episode of the DTx Podcast, Eugene Borukhovich sits down with Mike Pace, CEO and founder of PalmHealthCo, to delve into the latest developments and insights from the DTx industry from 2023 and to discuss what may be in store for 2024. Eugene and Mike cover various aspects of the DTx landscape, including the growing importance of FDA authorizations, the shift towards non-prescription solutions, and the maturation of the industry into operations and pricing. Learn more about the impact of FDA authorizations on scalability in the US healthcare system, the strategic integration of digital therapeutics with virtual care models, market consolidation, and the effects of decreased venture funding on the industry. 1. [04:00] What has the industry learned from Pear Therapeutics' initial growth and scaling and, ultimately, its bankruptcy? 2. [10:45] Mike mentions the importance of FDA authorizations for scalability in the US healthcare system. How does he foresee potential FDA approvals shaping the landscape for digital therapeutics in the near future? 3. [15:20] PalmHealthCo has been involved in integrating DTX with virtual care and pushing for a virtual first go-to-market model. How has this approach impacted their journey and success in the DTx space, and what are the potential implications for the industry as a whole? 4. [20:10] What is the importance of high-quality clinical evidence for achieving permanent listing under regulatory laws? How critical is this evidence generation for the future of digital therapeutics, and what challenges does Mike anticipate in this regard? 5. [25:40] Considering the rise of aggregators in the healthcare industry influencing the market for digital therapeutics, what strategies can DTx companies employ to navigate this evolving landscape? 6. [30:15] With the current state of venture funding and market consolidation in digital health, what advice does Mike have for startups in terms of maintaining a focus on positively impacting patients and families while navigating the industry's challenges? Tune in to the DTx Podcast to gain valuable insights into the evolving world of digital therapeutics and stay updated on the latest trends, legislative impacts, and entrepreneurial advice from industry leaders. Guest Links and Resources: Connect with Mike Pace on LinkedIn Host Links: Connect with Eugene Borukhovich: Twitter | LinkedIn Connect with Chandana Fitzgerald, MD: Twitter | LinkedIn Connect with YourCoach.health: Website | Twitter Check out Shot of Digital Health with Eugene and Jim Joyce: Website | Podcast App HealthXL: Website | Twitter | Join an Event Digital Therapeutics Podcast would not be possible without the support of leading DTx organizations. Thank you to: > Presenting Partner: Amalgam Rx > Contributing Partners and Sponsors: LSI | Bayer G4A | Lindus Health Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram

In this episode of the DTx Podcast, Eugene Borukhovich hosts Philip Heimann, CEO of Vivira, a prominent player in the DTx landscape in Germany. "The genesis of Vivira was the need for personalized movement therapy - we wanted to provide people with a solution that was made just for them," says Philip.  This necessity led to the development of an innovative digital therapeutic solution that has made a significant impact in the market. Eugene and Philip dive into the profound impact of the DiGA law in Germany, passed in 2019, on Vivira's market growth. This legislation enabled general reimbursement and physician involvement in prescribing the app, marking a pivotal turning point for the company and the broader DTx landscape in Germany. In addition, Philip sheds light on the challenges faced by DTx startups in understanding the market complexities and securing suitable funders. He stresses the importance of selecting investors who can offer long-term support and emphasizes the significance of focusing on long-term goals and building high-value companies. 1. [05:30] What challenges did Vivira face in the early stages, being almost exclusively angel-funded, and how did this contribute to the development of their DTx solution? 2. [10:45] What pivotal role has the DiGA law played in enabling Viveira's growth in the market, and what are the implications of this legislation for other DTx companies in Germany? 3. [15:20] How has Vivira's approach of not starting in the direct-to-consumer market and focusing on the DIGA prescription model influenced its journey and success in the DTx space? 4. [20:10] What is the significance of high-quality clinical evidence, particularly RCT studies, for achieving permanent listing under the DiGA law? 5. [25:40] What are the challenges and potential solutions regarding the activation of digital therapies prescribed by doctors? 6. [30:15] As a serial entrepreneur, what critical advice does Philip have for DTX startups in navigating the complexities of the market and choosing investors? Join us on the DTx Podcast for valuable insights into the world of digital therapeutics, covering topics from legislative impacts to entrepreneurial advice. Subscribe now to stay updated on the latest episodes and continue exploring the dynamic realm of DTx. Guest Links and Resources: Connect with Phillip Heimann on LinkedIn Visit Vivira Host Links: Connect with Eugene Borukhovich: Twitter | LinkedIn Connect with Chandana Fitzgerald, MD: Twitter | LinkedIn Connect with YourCoach.health: Website | Twitter Check out Shot of Digital Health with Eugene and Jim Joyce: Website | Podcast App HealthXL: Website | Twitter | Join an Event Digital Therapeutics Podcast would not be possible without the support of leading DTx organizations. Thank you to: > Presenting Partner: Amalgam Rx > Contributing Partners and Sponsors: LSI | Bayer G4A | Lindus Health Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram

In this episode, we hear from Josh Sackman, President and Co-founder of AppliedVR. AppliedVR, in their own words, provide virtual reality-based treatments that represent a comprehensive approach to chronic pain that empowers patients with accessible digital tools self-managed in their own home. In this episode, we cover: The origin story of AppliedVR Transitioning from an app store for health VR to focus pain management market Patient experience and the pain management pipeline Funding journey and key funding milestones The scientific hypothesis of "mind over matter" behind AppliedVR's approach and evidence generation journey The FDA approval process for AppliedVR and lessons learned for entrepreneurs. AppliedVR's current business hypothesis and scaling plan Market channels and scaling VR Guest Links and Resources: Connect with Josh Sackman on LinkedIn Visit www.appliedvr.io Host Links: Connect with Eugene Borukhovich: Twitter | LinkedIn Connect with Chandana Fitzgerald, MD: Twitter | LinkedIn Connect with YourCoach.health: Website | Twitter Check out Shot of Digital Health with Eugene and Jim Joyce: Website | Podcast App HealthXL: Website | Twitter | Join an Event Digital Therapeutics Podcast would not be possible without the support of leading DTx organizations. Thank you to: > Presenting Partner: Amalgam Rx > Contributing Partners and Sponsors: Akili | Big Health | Click Therapeutics | Lindus Health | Orion Pharma Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram

In a new episode of the pharmaphorum podcast, host Nicole Raleigh welcomes Joel Morse, CEO and co-founder of Curavit Clinical Research, and Andy Molnar, CEO of the Digital Therapeutics Alliance (DTA), for a discussion on why it is that digital therapeutics (DTx) are effective and safe, but not being prescribed.

In this replay episode, we hear from Sylvain Piquet, COO and Co-founder of Five Lives, the app that leverages the new science of brain aging, neuroplasticity, and cognitive reserve to help people improve their brain health and prevent cognitive decline and dementia. In this episode, we cover: The origin story of Five Lives and the motivation behind focusing on dementia and cognitive decline. The demographics benefitting from using Five Lives Gamifying behaviour change Evidence generation and funding journey The advantages of direct-to-consumer distribution through the app store How digital therapeutics can fit within the NHS The challenges of implementing DTx across UK, French, and German markets Guest Links and Resources: Connect with Sylvain Piquet on LinkedIn Visit www.fivelives.health Host Links: Connect with Eugene Borukhovich: Twitter | LinkedIn Connect with Chandana Fitzgerald, MD: Twitter | LinkedIn Connect with YourCoach.health: Website | Twitter Check out Shot of Digital Health with Eugene and Jim Joyce: Website | Podcast App HealthXL: Website | Twitter | Join an Event Digital Therapeutics Podcast would not be possible without the support of leading DTx organizations. Thank you to: > Presenting Partner: Amalgam Rx > Contributing Partners and Sponsors: Akili | Big Health | Click Therapeutics | Lindus Health | Orion Pharma Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram

In honor of Gift of Sight month we're replaying this insightful episode with Mark Wuttke, CEO of Dopavision. In their own words, Dopavision is pioneering the development of innovative solutions that target the eye's innate dopamine pathway to address unmet needs in ophthalmology using digitally delivered light.  Topics include: The background to Dopavision The pediatric Myopia vs adult Myopia markets Patient experience using Dopavision Changes to clinical trials and the mechanism of action Plans for commercialization Potential future applications to other ophthalmological conditions and neurological conditions  The future of OTC vs Rx Guest Links and Resources: Connect with Mark Wuttke on LinkedIn Visit Dopavision Listen to Digital Therapeutics for Pediatrics, Oncology and Managing Pain with Francesca Wuttke Episode PDF Host Links: Connect with Eugene Borukhovich: Twitter | LinkedIn Connect with Chandana Fitzgerald, MD: Twitter | LinkedIn Connect with YourCoach.health: Website | Twitter Check out Shot of Digital Health with Eugene and Jim Joyce: Website | Podcast App HealthXL: Website | Twitter | Join an Event Digital Therapeutics Podcast would not be possible without the support of leading DTx organizations. Thank you to: > Presenting Partner: Amalgam Rx > Contributing Partners and Sponsors: LSI | Bayer G4A | Lindus Health Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram

In this episode, we hear from Vijay Ravindran, founder and CEO of Floreo. Floreo allows therapy to be more engaging and happen anywhere, assisting people in practicing critical social skills at their own pace through immersive experiences, starting with adolescent Autism spectrum disorder. In this episode, we cover: The founding story of Floreo Market for autism and neurodiversity The child and caregiver experience using Floreo Funding journey and key milestones User and caregiver experience using Floreo Scientific hypothesis and evidence generation journey Scaling virtual reality in healthcare Guest Links and Resources: Connect with Vijay Ravindran on LinkedIn Visit floreovr.com Host Links: Connect with Eugene Borukhovich: Twitter | LinkedIn Connect with Chandana Fitzgerald, MD: Twitter | LinkedIn Connect with YourCoach.health: Website | Twitter Check out Shot of Digital Health with Eugene and Jim Joyce: Website | Podcast App HealthXL: Website | Twitter | Join an Event Digital Therapeutics Podcast would not be possible without the support of leading DTx organizations. Thank you to: > Presenting Partner: Amalgam Rx > Contributing Partners and Sponsors: LSI | Bayer G4A | Lindus Health Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram

We're seeing a broader consolidation of digital health solutions this year to bring together the amazing talent and the scientifically validated assets to drive scale in the market and improve unit economics. On the heels of last week's announcement of the merger between Fern Health and BehaVR tune into this replay episode to hear Eugene Borukhovich's conversation with Aaron Gani, Founder and CEO of BehaVR. BehaVR translates proven science into immersive and engaging XR therapeutics for mental and behavioral health. In this episode, we cover: Origin Story: Aaron Gani shares the origin story of BehaVR, starting from its inception in 2016 and the inspiration behind creating immersive XR therapeutics for mental and behavioral health. Funding Journey and Milestones: Walk through BehaVR's funding journey, uncovering the key milestones achieved with each funding round and how it has shaped the company's growth and impact in the digital therapeutics landscape. Patient Journey Using VR: Gain insights into the end customer experience offered by BehaVR, highlighting the effectiveness of immersive therapeutics in supporting mental well-being. Scientific Hypothesis and Evidence Generation: Explore the hypothesis that BehaVR is built upon and learn how their evidence generation journey is proving the effectiveness of their immersive XR therapeutics, showcasing the power of mind-body connections. Merging with OxfordVR and FDA Approval: Discover the decision-making process behind BehaVR's merger with OxfordVR and their journey towards FDA approval. Business Hypothesis and Scaling Plan: Delve into BehaVR's current business hypothesis and explore their scaling plan. Partnership with Sumitomo Dainippon: Aaron expands on BehaVR's partnership with Sumitomo Dainippon and discusses the commercial arrangement that led to this collaboration. Access to Care: Explore the accessibility of virtual reality therapy and its role in improving access to care for patients. Pear Therapeutics and the Future of PDTs: Aaron shares his thoughts on Pear Therapeutics and discusses the future of Prescription Digital Therapeutics (PDTs), providing insights into the evolving landscape of digital therapeutics and its potential to revolutionize mental health care. Guest Links and Resources: Connect with Aaron Gani on LinkedIn Visit BehaVR Episode PDF Host Links: Connect with Eugene Borukhovich: Twitter | LinkedIn Connect with Chandana Fitzgerald, MD: Twitter | LinkedIn Connect with YourCoach.health: Website | Twitter Check out Shot of Digital Health with Eugene and Jim Joyce: Website | Podcast App HealthXL: Website | Twitter | Join an Event Digital Therapeutics Podcast would not be possible without the support of leading DTx organizations. Thank you to: > Presenting Partner: Amalgam Rx > Contributing Partners and Sponsors: Akili | Bayer G4A | Lindus Health Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram

Learn about digital therapeutics. Synopsis: Every first and third Wednesday of the month, The Straits Times helps you make sense of health matters that affect you. Traditional healthcare is based on doctor and hospital visits, and it can take a long time to obtain appointments to see a healthcare professional. What if one day, an individual can be prescribed a digital therapy for their depression or other health issues remotely? He or she would not have to take any medications.  In this Health Check podcast episode, ST senior health correspondent Joyce Teo speaks to ​Professor Dean Ho, the director of the Institute for Digital Medicine (WisDM) at the National University of Singapore Yong Loo Lin School of Medicine and the head of the NUS biomedical engineering department, to find out more about digital therapeutics or DTx.  He's just written a book on DTx with two other researchers Mr Yoann Sapanel and Dr Agata Blasiak from the institute titled Medicine Without Meds: Revolutionising Healthcare With Digital Solutions. Highlights (click/tap above): 1:12 What is DTx? 9:24 Challenges of DTx? 10:57 How can DTx further personalise care?  23:05 Prof Ho's experiments Produced by: Joyce Teo (joyceteo@sph.com.sg), Ernest Luis, Amirul Karim & Eden Soh Edited by: Eden Soh Follow Health Check Podcast here and rate us: Channel: https://str.sg/JWaN Apple Podcasts: https://str.sg/JWRX Spotify: https://str.sg/JWaQ SPH Awedio app: https://www.awedio.sg/ Website: http://str.sg/stpodcasts Feedback to: podcast@sph.com.sg Read Joyce Teo's stories: https://str.sg/JbxN --- Discover more ST podcast channels: In Your Opinion: https://str.sg/w7Qt Asian Insider: https://str.sg/JWa7 Health Check: https://str.sg/JWaN Green Pulse: https://str.sg/JWaf Your Money & Career: https://str.sg/wB2m ST Sports Talk: https://str.sg/JWRE #PopVultures: https://str.sg/JWad Music Lab: https://str.sg/w9TX Discover ST Podcasts: http://str.sg/stpodcasts Discover BT Podcasts: https://bt.sg/pcPL --- Special edition series: True Crimes Of Asia (6 eps): https://str.sg/i44T The Unsolved Mysteries of South-east Asia (5 eps): https://str.sg/wuZ2 Invisible Asia (9 eps): https://str.sg/wuZn Stop Scams (10 eps): https://str.sg/wuZB Singapore's War On Covid (5 eps): https://str.sg/wuJa --- Follow our shows then, if you like short, practical podcasts! #healthcheckSee omnystudio.com/listener for privacy information.

In this episode, we hear from, Rich Brancaccio, Chief Innovation Officer of Revibe Technologies, and Lindsay Ayearst, Chief Scientific Officer of Revibe Technologies. In their own words, Revibe is a digital therapeutics company fusing behavioral science with technology and currently developing a new digital therapy for ADHD. In this episode, we cover: Founding story and funding milestones Child and caregiver experience using Revibe Quantifying attention & capturing focus data Evidence generation journey & clinical endpoints The ADHD market choice to focus on adolescent ADHD Lessons learned from the first wave of similar products and companies OTC vs PDT Guest Links and Resources: Connect with Lindsay Ayearst on LinkedIn Connect with Rich Brancaccio on LinkedIn Visit www.revibetech.com Host Links: Connect with Eugene Borukhovich: Twitter | LinkedIn Connect with Chandana Fitzgerald, MD: Twitter | LinkedIn Connect with YourCoach.health: Website | Twitter Check out Shot of Digital Health with Eugene and Jim Joyce: Website | Podcast App HealthXL: Website | Twitter | Join an Event Digital Therapeutics Podcast would not be possible without the support of leading DTx organizations. Thank you to: > Presenting Partner: Amalgam Rx > Contributing Partners and Sponsors: LSI | Bayer G4A | Lindus Health Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram

There are two kinds of people in the world, says Brent Vaughan — those who prefer to make incremental changes with a lower likelihood of failure, and those who aspire to fix (seemingly) intractable problems that have stymied others. Brent falls in the latter category. A serial entrepreneur, former venture capitalist, and current CEO of Cognito Therapeutics (a DTx company that specializes in neurodegenerative diseases), Brent is also uniquely positioned to evaluate the future of next generation digital therapeutics. Brent and Eugene talk about the differences between prescription and business-to-consumer DTx, the importance of engaging patients and users early on in the development of novel products, and the exciting potential of translational DTx solutions. Eugene's podcast partner, Brian Dolan, also pops in with a question. Guest Links and Resources: Connect with Brent Vaughan: LinkedIn Visit Cognito Therapeutics: Twitter | LinkedIn | Facebook | Website Host Links: Connect with Eugene Borukhovich: Twitter | LinkedIn Connect with Chandana Fitzgerald, MD: Twitter | LinkedIn Connect with YourCoach.health: Website | Twitter Check out Shot of Digital Health with Eugene and Jim Joyce: Website | Podcast App HealthXL: Website | Twitter | Join an Event Digital Therapeutics Podcast would not be possible without the support of leading DTx organizations. Thank you to: > Presenting Partner: Amalgam Rx > Contributing Partners and Sponsors: LSI | Bayer G4A | Lindus Health Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram

In this episode, we hear from Chan Yoon, MD, CEO of EverEx. EverEx is revolutionizing musculoskeletal rehabilitation with cutting edge AI, pose estimation technology, and evidence based treatments. In this episode, we cover: Insights into Digital Health in South Korea The EverEx creation journey The musculoskeletal health market in South Korea  Funding journey and challenges in the market Reimbursement environment in South Korea Entering the US Market with the product EverEx Rehab Clinical trials and patient experience using EverEx products Guest Links and Resources: Connect with Chan Yoon on LinkedIn Visit Everex.kr Episode PDF Host Links: Connect with Eugene Borukhovich: Twitter | LinkedIn Connect with Chandana Fitzgerald, MD: Twitter | LinkedIn Connect with YourCoach.health: Website | Twitter Check out Shot of Digital Health with Eugene and Jim Joyce: Website | Podcast App HealthXL: Website | Twitter | Join an Event Digital Therapeutics Podcast would not be possible without the support of leading DTx organizations. Thank you to: > Presenting Partner: Amalgam Rx > Contributing Partners and Sponsors: LSI | Bayer G4A | Lindus Health Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram

Cognitive behavioral therapy (CBT) is an evidence-based form of therapy that has been in use for decades. My guest in this episode believes that CBT can be applied to create better therapeutics, and, in fact, that's exactly what his company is called: Better Therapeutics. Dr. Mark Berman, the Chief Medical Officer at Better Therapeutics, explained that the goal of CBT is to “help people change some of those core beliefs, which then directly influence what we do on a day to day basis.” And while CBT was originally applied to help people with conditions like PTSD, anxiety and depression, the team at Better Therapeutics have developed their own variant of CBT to apply the core principles of CBT to the ideas that drive root behaviors like diet, exercise and other supportive lifestyle behaviors. Tune into this episode to hear how Better Therapeutics are creating new digital treatments to reverse the progression of cardiometabolic disease, improve quality of life and inform clinical decisions. In this episode, we cover: Patient experience using digital therapeutics for type 2 diabetes Nutritional CBT – Better Therapeutics innovative new form of Cognitive Behavioral Therapy Why companies are opting to create Prescription Digital Therapies rather than self-managed lifestyle apps What's next in the Better Therapeutics pipeline and how these decisions are made The future of Digital Therapeutic infrastructure Guest Links and Resources: Connect with Mark Berman on LinkedIn | Twitter Visit bettertx.com Host Links: Connect with Eugene Borukhovich: Twitter | LinkedIn Connect with Chandana Fitzgerald, MD: Twitter | LinkedIn Connect with YourCoach.health: Website | Twitter Check out Shot of Digital Health with Eugene and Jim Joyce: Website | Podcast App HealthXL: Website | Twitter | Join an Event Season 2 of Digital Therapeutics Podcast would not be possible without the support of leading DTx organizations. Thank you to: > Presenting Partner: Amalgam Rx > Contributing Sponsors: LSI | Bayer G4A | Lindus Health Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram

In this episode, we hear from Francesca Wuttke, Founder and CEO of Nen who is focusing on building prescription digital therapeutic at a cross-section of pediatrics, pain with an initial focus in oncology. In this episode, we cover: The background to nen and naming the company Gamifying CBT for treating children's pain Targeting the psychological aspects of pain Treating unmet needs in oncology Patient and parent experience Clinical evidence generation and PDT Business hypothesis, market entry, pricing and reimbursements Guest Links and Resources: Connect with Francesca Wuttke on LinkedIn Host Links: Connect with Eugene Borukhovich: Twitter | LinkedIn Connect with Chandana Fitzgerald, MD: Twitter | LinkedIn Connect with YourCoach.health: Website | Twitter Check out Shot of Digital Health with Eugene and Jim Joyce: Website | Podcast App HealthXL: Website | Twitter | Join an Event Season 2 of Digital Therapeutics Podcast would not be possible without the support of leading DTx organizations. Thank you to: > Presenting Partner: Amalgam Rx > Contributing Sponsors: LSI | Bayer G4A | Lindus Health Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram

Curio has announced positive data from the Supporting Maternal Mental Health and Emotional Regulation (SuMMER) trial demonstrating that MamaLift Plus has met its efficacy endpoints. This is a significant step towards providing better support for mothers during a crucial time.  In this Replay episode we hear from Shailja Dixit, CEO of Curio. In their own words: 'Curio is a Digital Therapeutics company with tailor-made Cognitive Behavioral Therapy programs for Women across the cycle of life – encompassing age groups, physiological conditions and social settings'. Topics include: The Founding Story of Curio Using Digital to Destigmatize Mental Health Support User experience of the MamaLift product Combining methods of Cognitive Behavioural Therapy, Interpersonal Therapy and Behavioural Activation Therapy  PDT vs Physician recommended DTx  Guest Links and Resources: Connect with Shailja Dixit on LinkedIn Visit https://www.curiodigitaltx.com/ Host Links: Connect with Eugene Borukhovich: Twitter | LinkedIn Connect with Chandana Fitzgerald, MD: Twitter | LinkedIn Connect with YourCoach.health: Website | Twitter Check out Shot of Digital Health with Eugene and Jim Joyce: Website | Podcast App HealthXL: Website | Twitter | Join an Event Digital Therapeutics Podcast would not be possible without the support of leading DTx organizations. Thank you to: > Presenting Partner: Amalgam Rx > Contributing Sponsors: Akili | LSI | Lindus Health Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram

In this special feed drop hear Eugene Borukhovich in conversation with Pharmaphorum Editor in Chief Jonah Comstock discussing what they saw and heard at DTx East in Boston. This year the digital therapeutics space took a hit with the downfall of Pear Therapeutics, one of the most well-known of the industry's still-active pioneers. Combined with Akili Interactive's hard pivot to OTC , some in the industry are wondering whether standalone prescription digital therapeutics are a failed experiment. Pharmaphorum Links and Resources: Connect with Jonah Comstock on LinkedIn Visit pharmaphorum.com Episode Write Up Pharmaphorum Podcast DTx Podcast Links and Resources:: Connect with Eugene Borukhovich: Twitter | LinkedIn Connect with Chandana Fitzgerald, MD: Twitter | LinkedIn Connect with YourCoach.health: Website | Twitter Check out Shot of Digital Health with Eugene and Jim Joyce: Website | Podcast App HealthXL: Website | Twitter | Join an Event Digital Therapeutics Podcast would not be possible without the support of leading DTx organizations. Thank you to: > Presenting Partner: Amalgam Rx > Contributing Partners and Sponsors: LSI | Bayer G4A | Lindus Health Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram

In this episode, we hear from Mark Wuttke, CEO of Dopavision. In their own words, Dopavision is pioneering the development of innovative solutions that target the eye's innate dopamine pathway to address unmet needs in ophthalmology using digitally delivered light.  Topics include: The background to Dopavision The pediatric Myopia vs adult Myopia markets Patient experience using Dopavision Changes to clinical trials and the mechanism of action Plans for commercialization Potential future applications to other ophthalmological conditions and neurological conditions  The future of OTC vs Rx Guest Links and Resources: Connect with Mark Wuttke on LinkedIn Visit Dopavision Listen to Digital Therapeutics for Pediatrics, Oncology and Managing Pain with Francesca Wuttke Episode PDF Host Links: Connect with Eugene Borukhovich: Twitter | LinkedIn Connect with Chandana Fitzgerald, MD: Twitter | LinkedIn Connect with YourCoach.health: Website | Twitter Check out Shot of Digital Health with Eugene and Jim Joyce: Website | Podcast App HealthXL: Website | Twitter | Join an Event Digital Therapeutics Podcast would not be possible without the support of leading DTx organizations. Thank you to: > Presenting Partner: Amalgam Rx > Contributing Partners and Sponsors: LSI | Bayer G4A | Lindus Health Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram

Fernando Alvim conversa com Moullinex & Xinobi sobre os 16 anos de DTX.

In this episode, we hear from Andrew Jenkinson and Niall O'Driscol, CEO's and Co-founders of vStream. vStream's primary focus is on the creation of compelling and engaging patient-centric experiences. Specializing in virtual reality, augmented reality, mixed reality, 360 video, immersive experiences, and digital installations Topics include: The background to vStream and the product ShineVR The funding journey Competition and the overall market in virtual reality Patient experience using ShineVR incorporating proven CBT techniques in a number of different spaces Scientific hypothesis and evidence generation process The proposition to employers for for corporate wellness Scaling plan and future pipeline Insights from a patient using ShineVR Guest Links and Resources: Connect with Niall O'Driscoll on LinkedIn Connect with Andrew Jenkinson on LinkedIn Visit vStream Episode PDF Host Links: Connect with Eugene Borukhovich: Twitter | LinkedIn Connect with Chandana Fitzgerald, MD: Twitter | LinkedIn Connect with YourCoach.health: Website | Twitter Check out Shot of Digital Health with Eugene and Jim Joyce: Website | Podcast App HealthXL: Website | Twitter | Join an Event Digital Therapeutics Podcast would not be possible without the support of leading DTx organizations. Thank you to: > Presenting Partner: Amalgam Rx > Contributing Partners and Sponsors: LSI | Bayer G4A | Lindus Health Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram

If you've been keeping up with the news you'll know that since March this year, Kranus Edera has been permanently listed as a digital health application by the Federal Institute for Drugs and Medical Devices. But the journey did not stop there. Last week Kranus Health achieved another milestone: successful price negotiations with the GKV-Spitzenverband, which is in charge of negotiating the reimbursement amount for new medications from pharmaceutical manufacturers. Kranus Edera has now secured one of the highest permanent reimbursement prices ever recorded for a DiGA in Germany: €235 (incl. VAT). To provide some context for this exciting development we're revisiting our episode with Jens Noertershaeuser, Founder & Co-CEO of Kranus Health. In their own words, Kranus Health's mission is to revolutionize men's health by providing innovative and accessible healthcare solutions. As one of only 10 companies with a permanent approval, Kranus Edera is the only the first digital health app (DiGA) for the treatment of erectile dysfunction. In this episode, we cover: The background to Kranus Health The focus on men's health and erectile dysfunction as a flagship product Products in development and the future of Kranus Health The funding journey Patient experience using the product Evidence generation and the DiGA process Insurance company reimbursment Guest Links and Resources: Connect with Jens Noertershaeuser on LinkedIn Visit kranushealth.com Host Links: Connect with Eugene Borukhovich: Twitter | LinkedIn Connect with Chandana Fitzgerald, MD: Twitter | LinkedIn Connect with YourCoach.health: Website | Twitter Check out Shot of Digital Health with Eugene and Jim Joyce: Website | Podcast App HealthXL: Website | Twitter | Join an Event Digital Therapeutics Podcast would not be possible without the support of leading DTx organizations. Thank you to: > Presenting Partner: Amalgam Rx > Contributing Partners and Sponsors: Akili | Bayer G4A | Lindus Health Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram

In this episode, we hear from Meri Beckwith, Co-founder of Lindus Health. In their own words, Lindus delivers end to end clinical trials for health tech and biotech pioneers. Topics include: The background and inception story of Lindus Health Lindus Health's place in the value chain Key funding milestones and achieving in a difficult market enviroment The unique aspects of clinical trials for DTx DTx as a medical device Pharmaceutical cclients in the DTx market The future for clinical trials and digitization Guest Links and Resources: Connect with Meri Beckwith on LinkedIn Visit Lindus Health Host Links: Connect with Eugene Borukhovich: Twitter | LinkedIn Connect with Chandana Fitzgerald, MD: Twitter | LinkedIn Connect with YourCoach.health: Website | Twitter Check out Shot of Digital Health with Eugene and Jim Joyce: Website | Podcast App HealthXL: Website | Twitter | Join an Event Digital Therapeutics Podcast would not be possible without the support of leading DTx organizations. Thank you to: > Presenting Partner: Amalgam Rx > Contributing Partners and Sponsors: LSI | Bayer G4A | Lindus Health Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram

In this episode, we hear from Susa Monacelli, General Manager at Propeller Health. In their own words Propeller Health is a precision digital health company on a mission to uplift every person living with chronic disease so they can take control of their health and live a better life. Topics include: The background to Propeller Health and the ResMed umbrella The original business hypothesis of ResMed and how this has evolved Patient experience using Propeller Health Differentiating propositions to health system, pharma and payers DTx vs. Disease Management 2.0 The future of prescription digital therapeutics Partnerships with health systems vs other routes to patient access Challenges holding the digital health industry back Guest Links and Resources: Connect with Susa Monacelli on LinkedIn Visit Propeller Health Episode PDF Host Links: Connect with Eugene Borukhovich: Twitter | LinkedIn Connect with Chandana Fitzgerald, MD: Twitter | LinkedIn Connect with YourCoach.health: Website | Twitter Check out Shot of Digital Health with Eugene and Jim Joyce: Website | Podcast App HealthXL: Website | Twitter | Join an Event Digital Therapeutics Podcast would not be possible without the support of leading DTx organizations. Thank you to: > Presenting Partner: Amalgam Rx > Contributing Partners and Sponsors: LSI | Bayer G4A | Lindus Health Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram

Have you heard? On August 22, Mahana Therapeutics announced a distribution and marketing partnership with Bayer's consumer health division. This partnership unites Mahana's proficiency in digital therapeutic advancement with Bayer's commitment to empowering individuals through cutting-edge digital solutions, all aimed at enabling greater personal health control. The full press release is linked below. In light of this, we're bringing you this replay episode with Simon Levy, CEO and Co-founder, and Ann Montgomery, Chief Product Officer at Mahana. In their own words, Mahana develops digital treatments for people living with chronic health conditions, and their first treatment, Mahana for IBS, is now available as an FDA-cleared app. In this episode, we cover: The founding story and funding journey of Mahana Complexities of the end to end patient experience The freemium model and how that translates into a PDT Evidence generation and FDA clearance process Scaling plans for PDTs Guest Links and Resources: Press Release about the Mahana and Bayer partnership Connect with Simon Levy on LinkedIn Connect with Ann Montgomery on LinkedIn Visit Mahana.com Host Links: Connect with Eugene Borukhovich: Twitter | LinkedIn Connect with Chandana Fitzgerald, MD: Twitter | LinkedIn Connect with YourCoach.health: Website | Twitter Check out Shot of Digital Health with Eugene and Jim Joyce: Website | Podcast App HealthXL: Website | Twitter | Join an Event Digital Therapeutics Podcast would not be possible without the support of leading DTx organizations. Thank you to: > Presenting Partner: Amalgam Rx > Contributing Partners and Sponsors: Akili | Big Health | Click Therapeutics | Lindus Health | Orion Pharma Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram

In this episode, we hear from Brian Wallace, CMO and Co-Founder of Calmsie. Calmsie in their own words are empowering children to develop emotional resilience from an early age. Calmsie creates engaging DTx video games designed to improve outcomes for children with depression and anxiety. In this episode, we cover: Translating addiction science to treat depression and anxiety in children The origin story and funding journey to Calmsie Parent and child experiences using the gamified program Emotional resilience training for prevention of mental health issues How the Calmsie video game affects the brain Evidence generation and deciding on PDT vs non-PDT routes The free workbook helping children understand the war in Ukraine Guest Links and Resources: Connect with Brian Wallace on LinkedIn Visit calmsie.ai YourCoach Health: Deep Dive Into Adolescent Health Episode PDF Host Links: Connect with Eugene Borukhovich: Twitter | LinkedIn Connect with Chandana Fitzgerald, MD: Twitter | LinkedIn Connect with YourCoach.health: Website | Twitter Check out Shot of Digital Health with Eugene and Jim Joyce: Website | Podcast App HealthXL: Website | Twitter | Join an Event Digital Therapeutics Podcast would not be possible without the support of leading DTx organizations. Thank you to: > Presenting Partner: Amalgam Rx > Contributing Partners and Sponsors: LSI | Bayer G4A | Lindus Health Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram

In this episode, we hear from David Kim, Managing Director at DigiTx Partners. In their own words DigiTX Partners is a venture firm focused on investing in and supporting supporting early stage startup companies in the digital health space. Launched in 2016 as a joint venture by Astellas Pharma And MPM Capital, DigiTx Partners remains one of a few venture funds exclusively dedicated to the digital health space. In 2018, Astellas continued its endeavor in digital health by forming the Rx Plus Digital Fund with DigiTx Partners as its investment manager. In this episode, we cover: What are the challenges faced by digital therapeutics in terms of distribution and clinical workflow? What hypothesis does DigiTx on DTx? What are the benefits of standalone vs drug+? Are DigiTx tracking any other modalities? What lessons have DigiTx learned so far? What will be the drivers for new capital injections in DTx especially? What are investors looking for ? What will the drivers of success going forward be for DTx?  How will the role of doctors, nurse & pharmacists change in order for the industry overall to scale PDT's? Guest Links and Resources: Connect with David Kim on LinkedIn Visit DigiTx Partners Episode PDF Host Links: Connect with Eugene Borukhovich: Twitter | LinkedIn Connect with Chandana Fitzgerald, MD: Twitter | LinkedIn Connect with YourCoach.health: Website | Twitter Check out Shot of Digital Health with Eugene and Jim Joyce: Website | Podcast App HealthXL: Website | Twitter | Join an Event Digital Therapeutics Podcast would not be possible without the support of leading DTx organizations. Thank you to: > Presenting Partner: Amalgam Rx > Contributing Partners and Sponsors: LSI | Bayer G4A | Lindus Health Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram

In this episode, we hear from Sean Khozin, Senior Partner at the investment firm Braven Partners. He focuses on advancing in innovations at the intersection of biology, technology and AI. Sean was previously the CEO of CancerLinQ and the Global Head of Data Strategy and Data Science at Johnson & Johnson. He had a successful tenure in the US federal government as the associate director of FDA's Oncology Center of Excellence and the founding executive director of FDA INFORMED, a data science and technology incubator he established under special authorities from the US department of health and human services. Topics include: How are Braven Partners incubating and supporting minimally viable ecosystems of companies that can make a difference? What are the goals of the Alliance for Artificial Intelligence in Healthcare? How can digital therapeutics developers ensure effective reimbursement for their products in the healthcare industry? How is the ethos of AI in healthcare speaking to a culture that is focused on safety without compromising innovation? How do we demystify new tools and technologies such as AI? How does the FDA think about regulating AI? What can digital therapeutic manufacturers companies, entrepreneurs and trailblazers learn from the Alliance for Artificial Intelligence in Healthcare (AAIH)? Guest Links and Resources: Connect with Sean Khozin on LinkedIn Visit Braven Partners Episode PDF Host Links: Connect with Eugene Borukhovich: Twitter | LinkedIn Connect with Chandana Fitzgerald, MD: Twitter | LinkedIn Connect with YourCoach.health: Website | Twitter Check out Shot of Digital Health with Eugene and Jim Joyce: Website | Podcast App HealthXL: Website | Twitter | Join an Event Digital Therapeutics Podcast would not be possible without the support of leading DTx organizations. Thank you to: > Presenting Partner: Amalgam Rx > Contributing Partners and Sponsors: LSI | Bayer G4A | Lindus Health Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram

When it comes to technology, the key for any organization is uptime. Every company has employees, whether a small business with one or two employees or a large enterprise with thousands. However, they all use technology, so it must be reliable and ensure the company has a strong network. But this is not easy to do. Technology is constantly changing, the needs of the business change, and customer expectations change. And this means companies, regardless of size, must keep their networks up to date. Having a dynamic digital strategy can help a company remain up-to-date. However, the plan must go beyond the fundamentals. It must leverage synergies and create efficiencies while always keeping the customer in mind. This episode discusses how large and small businesses can do this.

When it comes to technology, the key for any organization is uptime. Every company has employees, whether a small business with one or two employees or a large enterprise with thousands. However, they all use technology, so it must be reliable and ensure the company has a strong network. But this is not easy to do. Technology is constantly changing, the needs of the business change, and customer expectations change. And this means companies, regardless of size, must keep their networks up to date. Having a dynamic digital strategy can help a company remain up-to-date. However, the plan must go beyond the fundamentals. It must leverage synergies and create efficiencies while always keeping the customer in mind. This episode discusses how large and small businesses can do this.

In this episode, we hear from Benjamin Alouf, MD, Chief Medical Officer at Limbix. In their own words, Limbix is the first digital therapeutic for adolescent depression.  Big Health, the leading provider of non-drug digital treatments for mental health, has now acquired Limbix. In addition to health care providers, SparkRx will be made available to Big Health's employer, public sector, health systems and health plan customers, and through the company's strategic distribution agreements with pharmacy benefit managers (PBMs), significantly increasing nationwide access. In this episode, we cover: Origin of the company and story behind the name 'Limbix' The funding journey and key milestones achieved The choice to focus on the young adult population in particular Patient experience with SparkRx Defining good patient engagement in adolescent mental health Evidence generation and FDA submission process Business hypthothesis and scaling plan The future of the PDT market Guest Links and Resources: Connect with Benjamin Alouf, MD on LinkedIn Visit Limbix.com Episode PDF Big Health Expands into Adolescent Mental Health Through Acquisition of Limbix Host Links: Eugene Borukhovich: Twitter | LinkedIn Chandana Fitzgerald, MD: Twitter | LinkedIn YourCoach.health: Website | Twitter Shot of Digital Health with Eugene and Jim Joyce: Website | Podcast App HealthXL: Website | Twitter | Join an Event Digital Therapeutics Podcast would not be possible without the support of leading DTx organizations. Thank you to: > Presenting Partner: Amalgam Rx > Contributing Partners and Sponsors: Akili | Bayer G4A | Lindus Health Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram

In this episode, we hear from Eddie Martucci, co-founder and CEO of Akili. In their own words, Akili Interactive is a leading digital health company combining scientific and clinical rigor with ingenuity of the tech industry to reinvent medicine. In this episode, we cover: What factors have led to the increase in market demand for non-drug treatments for adult ADHD? How does Akili Interactive's prescription video game product, EndeavorRx, differ from traditional behavioral therapy for ADHD? What are the advantages and challenges of developing a digital therapeutic product that is available over-the-counter (OTC) without a prescription? How does the insurance coverage landscape impact the availability and adoption of digital therapeutics? What strategies does Akili Interactive employ to address the lack of awareness about digital therapeutics and their potential benefits? How does the user interface and experience of the EndeavorRx companion app, EndeavorRx Insight, contribute to higher compliance and better outcomes for families? How has Akili Interactive adapted and improved their commercial platform for scaling the distribution of their products? What advice does Eddie Martucci have for health executives? Guest Links and Resources: Connect with Eddie Martucci on LinkedIn Visit Akili Season 1 Episode: Akili's Revolutionary Digital Therapeutic with Eddie Martucci Co-Founder/CEO of Akili Episode PDF Host Links: Connect with Eugene Borukhovich: Twitter | LinkedIn Connect with Chandana Fitzgerald, MD: Twitter | LinkedIn Connect with YourCoach.health: Website | Twitter Check out Shot of Digital Health with Eugene and Jim Joyce: Website | Podcast App HealthXL: Website | Twitter | Join an Event Digital Therapeutics Podcast would not be possible without the support of leading DTx organizations. Thank you to: > Presenting Partner: Amalgam Rx > Contributing Partners and Sponsors: LSI | Bayer G4A | Lindus Health Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram

Let's face it, entrepreneurship is tough. While we're certainly seeing a much needed correction in the market this does not make it easier for any trailblazers out there. Sales cycles have slowed down. Decision making became even less transparent. And finally, funding became a numbers game. Now add to all of this, some recent bankruptcies and your head starts spinning. So what should a Digital Therapeutics entrepreneur do? Since we have the pleasure of hosting dozens upon dozens of leaders in the industry, we decided to put together a special episode with their advice to the awesome entrepreneurs out there. Guest Links and Resources: Connect with Acacia Parks on LinkedIn Visit Liquid Amber Connect with Ameya Phadke, Ph.D on LinkedIn Visit Chiesi Group Connect with Omar Manejwala, MD on LinkedIn Visit Dario Health Connect with Benjamin Alouf, MD on LinkedIn Visit Limbix Host Links: Connect with Eugene Borukhovich: Twitter | LinkedIn Connect with Chandana Fitzgerald, MD: Twitter | LinkedIn Connect with YourCoach.health: Website | Twitter Check out Shot of Digital Health with Eugene and Jim Joyce: Website | Podcast App HealthXL: Website | Twitter | Join an Event Digital Therapeutics Podcast would not be possible without the support of leading DTx organizations. Thank you to: > Presenting Partner: Amalgam Rx > Contributing Partners and Sponsors: LSI | Bayer G4A | Lindus Health Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram

In this episode, we hear from Jennifer Goldsack, CEO of Digital Medicine Society (DiMe). In their own words, DiMe is a global non-profit and the professional home for all members of the digital medicine community. In this episode, we cover: The origin and mission of DiMe Defining digital health, digital medicine and digital therapeutics Collaborating with the Digital Therapeutics Alliance Stakeholder management for patients and pharma The payer contracting framework Working across the healthcare ecosystem DiMe's approach to the science behind digital medicine and digital measurement products Guest Links and Resources: Connect with Jennifer Goldsack on LinkedIn Visit dimesociety.org Episode PDF Host Links: Connect with Eugene Borukhovich: Twitter | LinkedIn Connect with Chandana Fitzgerald, MD: Twitter | LinkedIn Connect with YourCoach.health: Website | Twitter Check out Shot of Digital Health with Eugene and Jim Joyce: Website | Podcast App HealthXL: Website | Twitter | Join an Event Digital Therapeutics Podcast would not be possible without the support of leading DTx organizations. Thank you to: > Presenting Partner: Amalgam Rx > Contributing Partners and Sponsors: LSI | Bayer G4A | Lindus Health Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram

In this episode, we hear from Joe Perekupka, CEO of Freespira. In their own words Freespira is 'the only medication-free, FDA-cleared digital therapeutic treatment proven to significantly reduce or eliminate symptoms of panic disorder, panic attacks and post-traumatic stress disorder in just 28 days.' In this episode, we cover: The founding story of Freespira The user experience from prescription to daily use The role of health coaches within Freespira Identifying potential candidates for Freespira The current landscape for panic disorder treatment and research into MDMA-assisted therapies Evidence generation to FDA approval journey Evolving pricing models The scope of PTSD across the US Guest Links and Resources: Connect with Joseph Perekupka on LinkedIn Visit freespira.com Host Links: Connect with Eugene Borukhovich: Twitter | LinkedIn Connect with Chandana Fitzgerald, MD: Twitter | LinkedIn Connect with YourCoach.health: Website | Twitter Check out Shot of Digital Health with Eugene and Jim Joyce: Website | Podcast App HealthXL: Website | Twitter | Join an Event Digital Therapeutics Podcast would not be possible without the support of leading DTx organizations. Thank you to: > Presenting Partner: Amalgam Rx > Sponsors: LSI | Bayer G4A | Lindus Health Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram

Jaggi Tut, Co-Owner of DTX, Inc. guides us on the pitfall on growing past five employees, overcoming challenges in building relationships, remembering why you left from where you came from, and...what to do when you have a driver who drives around in circles! 00:00 Introduction 00:26 The Breakthrough Is In The Decision 11:22 The Pitfall of Growing Past Five Employees 19:53 Overcoming The Challenge In Building Relationships 29:46 Final Thoughts: "A Tip Worth Meaning" 32:54 Credits Support small business owners, like you, celebrating BIG breakthroughs by supporting Small Business Celebration's Patreon page at: https://www.patreon.com/smallbusinesscelebration! #smallbusiness #smallbusinessowner #smallbusinesstips #smallbusinessidea #smallbusinessideas #smallbusinesstips #smallbusinesscelebration #smallbusinesscelebration #marcomgroup #homerunentertainment #dtxinc #dttr @smallbusinesscelebration @michaeliroberts @dtxinc @dttr @maangoldy Reach out to us at: https://smallbusinesscelebration.com Reach out to our guest at: https://dtx-inc.com at: http//dttr.us https://youtu.be/hKjCUm-2tBk

In this episode, Eugene sits down with Megan Coder, Chief Policy Officer of the Digital Therapeutics Alliance (DTA). Tune in to hear the exciting and positive advancements taking place in the digital therapeutics industry following the DTA Inaugural Summit. Topics include: The success of DTA's first summit in Washington DC Introducing a new definition of DTx The new DTx Evalution Toolkit Developing the new European DTx Policy Report in partnership with Healthware Guest Links and Resources: Connect with Megan Coder on LinkedIn Visit dtxalliance.org Episode PDF Host Links: Connect with Eugene Borukhovich: Twitter | LinkedIn Connect with Chandana Fitzgerald, MD: Twitter | LinkedIn Connect with YourCoach.health: Website | Twitter Check out Shot of Digital Health with Eugene and Jim Joyce: Website | Podcast App HealthXL: Website | Twitter | Join an Event Digital Therapeutics Podcast would not be possible without the support of leading DTx organizations. Thank you to: > Presenting Partner: Amalgam Rx > Contributing Partners and Sponsors: LSI | Bayer G4A | Lindus Health Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram

In our previous episode, we covered how companies can harness the power of digital therapeutics to improve their brand's value proposition. But what does it really take to get a clinically validated prescription digital product to market? Dr. Shaheen Lakhan, Chief Medical Officer, Click Therapeutics joins us on the second episode of our two-part series on digital therapeutics to discuss the diligence required to help regulators, health plans and payers, clinicians, and patients understand the potential of these digital solutions outside of entertainment—and how to apply the principles of traditional, biopharmaceutical types of drug development, validation and regulatory exercises to get them into the hands of patients. Listen to part one of our conversation on digital therapeutics with Austin Speier, Chief Strategy Officer of Click Therapeutics, here.  And for a deeper dive into how companies can implement DTx to expand or augment the potential of their pharmaceutical and biologic therapeutic assets, read our article 10 Ways to Optimize and Accelerate Brand Performance using Prescription DTx.The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you'll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health. Like what you're hearing? Be sure to rate and review us! We want to hear from you! If there's a topic you'd like us to cover on a future episode, contact us at podcast@syneoshealth.com.

Digital therapeutics (DTx) are projected to be $50 billion industry by 2025. While many minds may immediately jump to unregulated companion apps when they hear “digital,” there are also clinically validated prescription digital products that act complementary to or in combination with traditional biopharmaceutical therapies. As these prescription DTx gain traction, how can companies harness their power to improve their brand's value proposition? In this first of two episodes on DTx, Michael Sarshad, Managing Director, Commercial Advisory at Syneos Health and Austin Speier, Chief Strategy Officer, Click Therapeutics, join the podcast to discuss the growing market and opportunities for DTx across the product lifecycle, where DTx can add value and ways to think about how to integrate them into a brand strategy. For a deeper dive into how companies can implement DTx to expand or augment the potential of their pharmaceutical and biologic therapeutic assets, read our article 10 Ways to Optimize and Accelerate Brand Performance using Prescription DTx.The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you'll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health. Like what you're hearing? Be sure to rate and review us! We want to hear from you! If there's a topic you'd like us to cover on a future episode, contact us at podcast@syneoshealth.com.